COVIDH TECHNOLOGIES LIMITED

iSERA Lifesciences Ltd has announced that its Board of Directors will convene on November 4, 2026, to consider and approve the standalone un-audited financial results for the quarter and half-year ended September 30, 2026. Concurrently, the trading window for designated persons will be closed from October 1, 2026, until 48 hours after the results are declared, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Archana Kakasaheb Lonkar, a promoter of iSERA Lifesciences Limited, has sold 4,95,000 equity shares, representing 2.01% of the total share capital. The sale occurred via Preferential Allotment (Share Swap) on October 1, 2026. Following the transaction, her holding decreased from 7,00,000 shares (8.32%) to 11,95,000 shares (4.86%). The total equity share capital of the company post-transaction is Rs. 24,59,17,720/-, comprising 2,45,91,772 equity shares of Rs. 10/- each.

Nandkumar Kadam, Promoter of iSERA Lifesciences Limited, has acquired 15,71,500 equity shares through a Preferential Allotment (Share Swap). This transaction, which occurred on October 01, 2026, resulted in a change in his shareholding. The total equity capital before the acquisition was ₹8,40,89,720, representing 84,08,972 equity shares. After the acquisition, the total equity capital stands at ₹24,59,17,720, comprising 2,45,91,772 equity shares. The disclosure was made on October 05, 2026, in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dhairyasheel Yadav, a promoter of iSERA Lifesciences Limited, has acquired 4,50,500 equity shares through a Preferential Allotment (Share Swap). This transaction increases his total holding to 11,15,000 shares, representing 13.26% of the total diluted share capital. The acquisition occurred on October 1, 2026, following a Board of Directors meeting.

Sumeet Dhanraj Garad, a promoter of iSERA Lifesciences Ltd, has increased his shareholding in the company through a preferential allotment via a share swap. Prior to the acquisition, Garad held 1,00,000 shares, representing 1.19% of the total share capital. After the acquisition, his holding increased to 12,92,000 shares, representing 4.06% of the total share capital. The acquisition was executed on October 1, 2026, through a 1:1 share swap ratio, where one Equity Share of iSERA Lifesciences Limited was issued for every one Equity Share of iSERA Biological Limited held. This transaction is a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Pratap Dadasaheb Deshmukh and Persons Acting in Concert (PACs), the Promoter Group of iSERA Lifesciences Limited, have disclosed a change in their shareholding following a Preferential Allotment (Share Swap) on October 01, 2026. The total shareholding of the Promoter Group increased from 49,30,001 shares (58.63%) to 1,35,43,001 shares (55.07%). This transaction represents a net increase of 86,13,000 shares, resulting in a decrease of 3.56% in their overall stake relative to the total diluted capital. The equity share capital of the company has significantly increased from ₹8,40,89,720 to ₹24,59,17,720.

iSERA Lifesciences Ltd (formerly Covidh Technologies Limited) announced board approval for the allotment of 1,61,82,800 fully paid-up equity shares. These shares, with a face value of ₹10 each, are issued at ₹48.20 per share (including a premium of ₹38.20) on a preferential basis via share swap. The swap ratio is 1:1, meaning one equity share of iSERA Lifesciences for every one equity share of iSERA Biological Limited. This transaction was previously approved by shareholders via postal ballot/e-voting and received in-principle approval from BSE. The allotment is to individuals categorized under Promoter, Promoter Group, and Non-Promoter categories.

iSERA Lifesciences Ltd (formerly Covidh Technologies Limited) announced that its Board of Directors, in a meeting held on October 01, 2026, approved the allotment of 1,61,82,800 fully paid-up equity shares. These shares, with a face value of ₹10 each, were issued at a price of ₹48.20 per share, including a premium of ₹38.20. The allotment is on a preferential basis via Share Swap at a 1:1 ratio with iSERA Biological Limited. This follows the Board's earlier approval on April 21, 2026, and subsequent shareholder approval via postal ballot/e-voting declared on May 21, 2026. BSE granted its in-principle approval on September 18, 2026. The shares are allotted to individuals categorized under Promoter and Non-Promoter groups.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with the company's code of conduct and SEBI regulations regarding insider trading. The window will be shut from October 01, 2026, and will reopen 48 hours after the announcement of the un-audited financial results for the quarter and half-year ended September 30, 2026. The date of the board meeting to approve these results will be communicated later.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has announced its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 3:00 PM IST via video conference. The company will submit its Annual Report for the financial year 2025-26 and the Notice convening the AGM. The Annual Report and Notice are being sent electronically to members registered by August 28, 2026. Remote e-voting will be open from September 26 to September 28, 2026. MUFG Intime India Pvt. Ltd. has been engaged for the e-voting procedure. The Annual Report and Notice are available on the company's website and MUFG's website.